Krystal Biotech (1KRYS) Stock Overview
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1KRYS from our risk checks.
1KRYS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Krystal Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$211.90 |
| 52 Week High | US$218.80 |
| 52 Week Low | US$120.35 |
| Beta | 0.46 |
| 1 Month Change | 8.53% |
| 3 Month Change | 32.64% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 45.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1KRYS | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -0.05% | -3.6% | 2.8% |
| 1Y | n/a | 14.6% | 29.0% |
Return vs Industry: Insufficient data to determine how 1KRYS performed against the Italian Biotechs industry.
Return vs Market: Insufficient data to determine how 1KRYS performed against the Italian Market.
Price Volatility
| 1KRYS volatility | |
|---|---|
| 1KRYS Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IT Market | 6.9% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: 1KRYS has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1KRYS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 275 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
| 1KRYS fundamental statistics | |
|---|---|
| Market cap | €6.07b |
| Earnings (TTM) | €170.19m |
| Revenue (TTM) | €319.28m |
Is 1KRYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1KRYS income statement (TTM) | |
|---|---|
| Revenue | US$373.16m |
| Cost of Revenue | US$21.41m |
| Gross Profit | US$351.76m |
| Other Expenses | US$152.85m |
| Earnings | US$198.91m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.86 |
| Gross Margin | 94.26% |
| Net Profit Margin | 53.30% |
| Debt/Equity Ratio | 0% |
How did 1KRYS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 21:56 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krystal Biotech, Inc. is covered by 24 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Alec Stranahan | BofA Global Research |
| Justin Zelin | B. Riley Securities, Inc. |